Human Parvovirus B19 NS1 Protein Aggravates Liver Injury in NZB/W F1 Mice

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Tsai, Chun Chou ^a   Chiu, Chun Ching ^a,b   Hsu, Jeng Dong ^a,c   Hsu, Huai Sheng ^a   Tzang, Bor Show ^a,c   Hsu, Tsai Ching ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NONSTRUCTURAL PROTEIN 1; PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN PARVOVIRUS B19; LIVER INJURY; LIVER STRUCTURE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CYCLOOXYGENASE 2; ENDOTOXINS; FEMALE; HEPATOCYTES; I-KAPPA B KINASE; I-KAPPA B PROTEINS; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED NZB; NITRIC OXIDE SYNTHASE TYPE II; OPEN READING FRAMES; PARVOVIRUS B19, HUMAN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84875348657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059724     Document Type: Article

References (41)

1. Hahn BH (1993) An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Williams and Wilkins. 69-76.
2. Mackay IK, Taft LI, Cowling DC, (1959) Lupoid hepatitis and the hepatic lesions of SLE. Lancet 5: 65-69.
3. Runyon, LaBrecque DR, Anuras S, (1980) The spectrumof liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 69: 187-194.
4. Abraham S, Begum S, Isenberg D, (2004) Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63: 123-129.
5. Young NS, Brown KE, (2004) Parvovirus B19. N Engl J Med 350: 586-597.
6. Lehmann HW, Modrow S, (2003) Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2: 218-223.
7. Bock CT, Klingel K, Aberle S, Duechting A, Lupescu A, et al. (2005) Human parvovirus B19. A new emerging pathogen of inflammatory cardiomyopathy. J. Vet. Med. B: Infect. Dis. Vet. Public Health 52: 340-343.
8. Servant-Delmas A, Lefrère JJ, Morinet F, Pillet S, (2010) Advances in human B19 erythrovirus biology. J Virol 84: 9658-9665.
9. Hatakka A, Klein J, He R, Piper J, Tam E, et al. (2011) Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol 49: 3422-3424.
10. Sun L, Zhang JC, Jia ZS, (2011) Association of parvovirus B19 infection with acute icteric hepatitis in adults. Scand J Infect Dis 43: 547-549.
11. Sun L, Zhang JC, (2012) Acute fulminant hepatitis with bone marrow failure in an adult due to parvovirus B19 infection. Hepatology 55: 329-330.
12. Shiraishi A, Hoshina T, Ihara K, Doi T, Ohga S, et al. (2012) Acute liver failure as the initial manifestation of Wilson disease triggered by human parvovirus b19 infection. Pediatr Infect Dis J. 31: 103-104.
13. Von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S, (2003) Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 48: 1939-1947.
14. Sève P, Ferry T, Koenig M, Cathebras P, Rousset H, et al. (2005) Lupus-like presentation of parvovirus B19 infection. Semin Arthritis Rheum 34: 642-648.
15. Tzang BS, Chen DY, Tsai CC, Chiang SY, Lin TM, et al. (2010) Human parvovirus B19 nonstructural protein NS1 enhanced the expression of cleavage of 70 kDa U1-snRNP autoantigen. J Biomed Sci. 17: 40.
16. Chen DY, Tzang BS, Chen YM, Lan JL, Tsai CC, et al. (2010) The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta 411: 1084-1089.
17. Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, et al. (2007) The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clin Chim Acta 378: 59-65.
18. Tzang BS, Tsai CC, Tsay GJ, Wang M, Sun YS, et al. (2009) Anti-human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis. Clin Chim Acta 405: 76-82.
19. Kajigaya S, Fujii H, Field AM, Rosenfeld S, Anderson LJ, et al. (1991) Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 88: 4646-4650.
20. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
21. Towbin H, Staehelin T, Gordon J, (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc. Natl Acad Sci USA 76: 4350-4354.
22. Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, et al. (1997) Rediske J, Skovron ML, Abramson SB. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 40: 1810-1816.
23. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF, (2010) Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum. 62: 2064-2072.
24. Wang HP, Hsu TC, Hsu GJ, Li SL, Tzang BS, (2009) Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice. Eur J Pharmacol 607: 102-6.
25. Fung HB, Kirschenbaum HL, (1999) Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. Clin. Ther 21: 1131-1157.
26. Weinberg JB, (2000) Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol Res 22: 319-341.
27. Xu L, Zhang L, Yi Y, Kang HK, Datta SK, (2004) Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10: 411-415.
28. Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK, (2007) Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 56: 4132-4141.
29. Goetzl EJ, Banda MJ, Leppert D, (1995) Matrix metalloproteinases and immunity. J Immunol 156: 1-4.
30. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E, (2002) Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127: 393-398.
31. Ainiala H, Hietaharju A, Dastidar P, Loukkola J, Lehtimäki T, et al. (2004) Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 50: 858-865.
32. Ram M, Sherer Y, Shoenfeld Y, (2006) Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26: 299-307.
33. Prince HE (2005) Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers Suppl 1: S44-S49.
34. Sato H, Kita M, Seiki M, (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 268: 23460-23468.
35. Li W, Li H, Bocking AD, Challis JR, (2010) Tumor necrosis factor stimulates matrix metalloproteinase 9 secretion from cultured human chorionic trophoblast cells through TNF receptor 1 signaling to IKBKB-NFKB and MAPK1/3 pathway. Biol Reprod 83: 481-487.
36. Doerig C, Hirt B, Antonietti JP, Beard P, (1990) Nonstructural protein of parvoviruses B19 and minute virus of mice controls transcription. J Virol 64: 387-396.
37. Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, et al. (1996) A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70: 8485-8491.
38. Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, et al. (1999) Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 73: 8762-8770.
39. Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, et al. (2001) Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82: 3011-3019.
40. Burnet FM, Holmes MC, (1965) The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus. Australas Ann Med 14: 185-91.
41. Pugliese A, Beltramo T, Torre D, Roccatello D, (2007) Parvovirus B19 and immune disorders. Cell Biochem Funct 25: 639-641.